Anti-Leishmanial Effect of Oral Zinc Sulfate in Acute Cutaneous Leishmaniasis: A Mini-review
International Journal of TROPICAL DISEASE & Health,
Cutaneous Leishmaniasis (CL) is an endemic parasitic infection caused by various Leishmania species, with a specific predisposition of each species into a particular geographical area. Cutaneous lesions can either be a single, limited skin lesion or multiple, large, locally destructions skin lesions. Several therapies are proposed for CL, but severe side effects, high costs, and incomplete efficacy make researchers find replaceable therapies. Since the usage of zinc sulfate as a therapeutic agent has a long history in treating of various dermatological diseases, Zinc plays an essential role in the development and function of innate immunity cells (neutrophils and natural killer cells), which play significant roles in killing parasites. It also has a significant inhibitory effect on key enzymes involved in the carbohydrate metabolism and virulence of L. major and L.tropica. Therefore, its use as an oral therapy for CL might represent a significant addition to the armamentarium of anti-leishmanial medications. This review summarizes and discusses previous and recent findings regarding the therapeutic roles of oral zinc sulfate in cutaneous leishmaniasis therapy.
- Cutaneous leishmaniasis
- zinc sulfate
- cutaneous lesions
- oral formulation
How to Cite
Desjeux P. Leishmaniasis: Current Situation and New Perspectives. Comp ImmunolMicrobiol Infect Dis. 2004;27:305-318.
Blum J, Buffet P, Visser L, Harms G, Bailey MS, Caumes E. Leish Man. Recommendations for Treatment of Cutaneous and Mucosal Leishmaniasis in Travelers. J Travel Med. 2014;21(2):116–129.
Uzun S, Gürel MS, Durdu M, Akyol M, Fettahlıoğlu Karaman B, Aksoy M. Clinical practice guidelines for the diagnosis and treatment of cutaneous leishmaniasis in Turkey. Int J Dermatol. 2018;57(8):973–982.
Bryceson ADM, Hay RJ. Parasitic worms and protozoa in Rook Textbook of Dermatology, R. H. Champion, J. L. Burton, D. A. Burns, and S. M. Breathnach, Eds. Blackwell Science, London, UK, 6 edition. 1998;1411–1412.
Oumeish OY. Cutaneous leishmaniasis: a historical perspective.Clin Dermatol. 1999; 17(3):249–254.
Lawn SD, Yardley V, Vega-Lopez F, Watson J, Lockwood D.N. New World Cutaneous Leishmaniasis in Returned Travelers: Treatment Failures Using Intravenous Sodium Stibogluconate. Trans R Soc Trop Med Hyg. 2003;97:443-445.
Neldner KH. Zinc deficiency and the skin. In S Maddin, Current Dermatological Therapy, WB Saunders & Co., Philadelphia 1982b;50-54.
Gupta M, Mahajan VK, Mehta KS, Chauhan PS. Zinc Therapy in Dermatology A Review. Dermatol Res Pract. 2014;1–11.
Prasad A.S. Clinical, immunological, anti-inflammatory and antioxidant roles of zinc. Exp Gerontology. 2008; 43:370–377.
Shankar A.H, Prasad A.S. Zinc and immune function: the biological basis of altered resistance to infection. Am J ClinNutr. 1998; 68 (suppl):447S– 463S.
Prasad AS. Zinc: role in immunity, oxidative stress and chronic inflammation. Curr Opin Clin Nutr Metab Care. 2009; 12:646-652.
Prasad A.S. Zinc disorders. In: Ston J. ed. Dermatology Immunology and Allergy. St Louis: C. V. Mosbey and Co., 1985: 759-65.
Rink L., Kirchner H., Zinc-Altered Immune Function and Cytokine Production. J Nutr. 2000;130(5):1407S–1411S. DOI: https://doi.org/10.1093/jn/130.5.1407S.
Steigerwald M., Moll H. Leishmania major modulates chemokine and chemokine receptor expression by dendritic cells and affects their migratory capacity. Infect Immun. 2005;73:2564.
Ritter U, Moll H. Monocyte chemotactic protein-I stimulates the killing of Leishmania major by human monocytes, acts synergistically with IFNgamma and is antagonized by IL-4. Eur J Immunol. 2000;30:3111-20.
Constantinescu CS, Hondowicz BD, Elloso MM, Wysocka M, Trinchieri G, Scott P. The role of IL-12 in the maintenance of an established Thl immune response in experimental leishmaniasis. Eur J Immunol. 1998;28:2227-33.
Griffthis WAD, Croft SL. Cutaneous leishmaniasis. Postgrad Doctor Middle East 1980;3:338-40.
Griffiths WAD, Sodeify M. Use of metronidazole in cutaneous leishmaniasis. Arch Dermatol 1976;112:1791.
Al-MullaHummadi YM, Al-Bashir NM, Najim RA. The mechanism behind the antileshmanial effect of zinc sulphate II effects on the enzymes of the parasites.Ann Trop Med Parasitol. 2005; 99:131-139.
Bar-Even A, Flamholz A, Noor E, Milo R. Rethinking glycolysis: on the biochemical logic of metabolic pathways. Nat Chem Biol. 2012;8:509–517.
Najim RA, Sharquie KE, Faarjou IB. Zinc sulfate in the treatment of cutaneous leishmaniasis: an in vitro and animal studyMemInst Oswaldo Cruz. 1998; 93(6):831-837.
Fattahi Bafghi A, Noorbala M, Taghi Noorbala M, Aghabagheri M. Anti Leishmanial Effect of Zinc Sulphate on the Viability of Leishmania tropica and L. major Promastigotes. Jundishapur J Microbiol. 2014;7(9):e11192.
Zamani F, Alavi AM. Therapeutic effect of sodium selenite and zinc sulphate as supplementary with meglumineantimoniate against cutaneous leshmaniasis in BALB/C MICE.Iranian J Parasitol.2010;5(3):11-19.
Sharquie KE, Najim RA., Farjou IB, Al-Timimi DJ. Oral Zinc Sulphate in the treatment of acute cutaneousleishmaniasis cutaneous. Clin Exp Dermatol. 200l;26(1): 21-26.
Yazdan Panah MJ, Mostoufi SK, Soleimani M. Oral Zinc Sulfate in the treatment of acute cutaneous Leishmaniasis. Iranian Red Crescent Medical J.2007; 9(4):205-208.
Yazdan panah MJ, Banihashemi M, Pezeshkpoor F, Khajedaluee M, Famili S, Rodi IT, Yousefzadeh H. Comparison of oral zinc sulphate with systemic meglumineantimoniate in the treatment of cutaneous leshmaniasis. Dermatol Res Pract. 2011; 269515-4.
Sharquie KE, Noaimi AA, Al-Salam WS. Treatment of acute cutaneous leshmaniasis by oral zinc sulfate and oral ketoconazole singly and in combination. Dermatol Sci Appl. 2016;6:105-115.
Miranda-Verastegui C, Tulliano G, Gyorkos TW, Calderon W, Rahme E, Ward B, Matlashewski G. First-Line Therapy for Human Cutaneous Leishmaniasis in Peru Using the TLR7 Agonist Imiquimod in Combination with Pentavalent Antimony. PLoSNegl Trop Dis. 2000;3(7):e491.
Berman JD, Waddell D, Hanson BD. Biochemical Mechanisms of the Antileishmanial Activity of Sodium Stibogluconate. Antimicrob Agents Chemother. 1985;27:916-920.
Abstract View: 212 times
PDF Download: 33 times